Study Reveals Organ-Specific Metabolic Responses to Fenofibrate Treatment in Rats
A comprehensive study examining fenofibrate’s effects reveals striking differences in how liver and kidney tissues respond to the medication. Researchers found significantly stronger metabolic activation in liver tissue compared to kidneys, with implications for understanding drug mechanisms and potential side effects.
Differential Organ Response to Common Medication
New research published in Scientific Reports reveals that fenofibrate, a commonly prescribed lipid-lowering medication, activates metabolic pathways differently in liver and kidney tissues, according to the study findings. The five-day rat exposure study demonstrated that while both organs showed responses to the drug, the liver exhibited significantly stronger activation of lipid metabolism pathways than the kidney.